NeuroTrauma Sciences, LLC (NTS), a US-based private biopharmaceutical company, announced on Wednesday that it has named Marc de Somer, MD, ScD, MPH, MSc, MBA as its new chief medical officer and Martin Rabe, MSc as its new executive vice president of Regulatory Affairs and Quality Assurance.

Dr de Somer has over 30 years of leadership in the biopharmaceutical industry. He has served at Sandoz/Novartis Pharmaceuticals, in clinical development leadership responsibilities for the European, the UK, and the US market. He co-founded three VC-backed clinical-stage neuroscience start-ups where he held the position of chief medical officer and head of Research & Development. He has served as CMO for Maxona Pharmaceuticals, vice president of Product Development, Neuroscience at PPD (part of Thermo Fisher Scientific) and vice president of Clinical Development and Medical Affairs for Alkermes, Inc.

Rabe has more than 25 years of global drug development and regulatory expertise with biologics and small molecules focusing on neurological diseases, and has helped manage and support six new drug/biologic approvals. He has worked as senior vice president and head of Global Regulatory Affairs and Quality Assurance for Kira Pharmaceuticals and served for a decade of his career at Eisai, Inc., in senior global regulatory positions that include vice president and head of Global Regulatory Strategy and Commercial Regulatory Affairs Neurology Business Group; and executive director, Global Regulatory Affairs, He has also served for six years at Pfizer, Inc., in worldwide regulatory strategy positions, and at Merck & Co.